• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黑色素瘤过度诊断:我们知道什么?我们能做什么?

Melanoma overdiagnosis: What do we know and what do we do?

机构信息

MBChB, FRCPA, Senior Lecturer, Faculty of Medicine, The University of Queensland, Brisbane, Qld; Distinguished Visiting Professor TUMS, Department of Dermatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

BMath, BSc, BSc (Hons), Intercalated MD, PhD, Faculty of Medicine, The University of Queensland, Brisbane, Qld.

出版信息

Aust J Gen Pract. 2024 Sep;53(9):612-616. doi: 10.31128/AJGP-02-24-7176.

DOI:10.31128/AJGP-02-24-7176
PMID:39226593
Abstract

BACKGROUND

Melanoma overdiagnosis occurs when melanomas, not destined to cause morbidity or death in a patient's lifetime, are identified and treated.

OBJECTIVE

This study considers the causes and magnitude of melanoma overdiagnosis in Australia. We also speculate about a possible benefit of overdiagnosis in Australia; namely, a reduction in excess deaths in the geographical areas where melanoma is diagnosed most frequently.

DISCUSSION

Overdiagnosis can arguably be mitigated by factors that reduce the number of lesions treated for each melanoma identified. Data from the Australian Cancer Atlas show that there is a reduction in excess deaths from melanoma in geographical areas where diagnostic rates are higher (Pearson correlation coefficient r=-0.5978, 95% CI: -0.6243 to -0.5699, P<0.0001); this being the strongest inverse correlation observed among the 20 cancer types in the Atlas. Is early diagnosis of actual life-threatening melanomas in these geographical regions impacting survival? Further research is planned.

摘要

背景

当黑色素瘤在患者有生之年不会导致发病或死亡的情况下被发现和治疗时,就会出现黑色素瘤过度诊断。

目的

本研究考虑了澳大利亚黑色素瘤过度诊断的原因和程度。我们还推测了过度诊断在澳大利亚可能存在的益处,即在诊断黑色素瘤最频繁的地理区域减少超额死亡人数。

讨论

通过减少每个被诊断出的黑色素瘤所治疗的病变数量,可以减轻过度诊断的问题。澳大利亚癌症图谱的数据显示,在诊断率较高的地理区域,黑色素瘤的超额死亡人数有所减少(皮尔逊相关系数 r=-0.5978,95%置信区间:-0.6243 至-0.5699,P<0.0001);这是图谱中 20 种癌症类型中观察到的最强负相关。在这些地理区域,早期诊断出实际危及生命的黑色素瘤是否会影响生存率?计划进行进一步的研究。

相似文献

1
Melanoma overdiagnosis: What do we know and what do we do?黑色素瘤过度诊断:我们知道什么?我们能做什么?
Aust J Gen Pract. 2024 Sep;53(9):612-616. doi: 10.31128/AJGP-02-24-7176.
2
The effect of screening on melanoma incidence and biopsy rates.筛查对黑色素瘤发病率和活检率的影响。
Br J Dermatol. 2022 Oct;187(4):515-522. doi: 10.1111/bjd.21649. Epub 2022 Jun 28.
3
Screening for reducing morbidity and mortality in malignant melanoma.筛查以降低恶性黑色素瘤的发病率和死亡率。
Cochrane Database Syst Rev. 2019 Jun 3;6(6):CD012352. doi: 10.1002/14651858.CD012352.pub2.
4
Ecological evidence for melanoma overdiagnosis in Denmark.丹麦黑色素瘤过度诊断的生态学证据。
Br J Dermatol. 2024 Aug 14;191(3):318-319. doi: 10.1093/bjd/ljae206.
5
6
Estimating the magnitude of cancer overdiagnosis in Australia.估算澳大利亚癌症过度诊断的程度。
Med J Aust. 2020 Mar;212(4):163-168. doi: 10.5694/mja2.50455. Epub 2019 Dec 19.
7
Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia.估算澳大利亚原位黑色素瘤和薄型侵袭性黑色素瘤过度诊断的严重程度和医疗保健成本。
Br J Dermatol. 2024 Nov 18;191(6):906-913. doi: 10.1093/bjd/ljae296.
8
Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.澳大利亚前列腺癌过度诊断的终身风险:使用新的终身风险方法定量评估澳大利亚前列腺癌筛查相关的过度诊断风险。
BMJ Open. 2019 Mar 10;9(3):e022457. doi: 10.1136/bmjopen-2018-022457.
9
Ecological study estimating melanoma overdiagnosis in the USA using the lifetime risk method.使用终生风险法对美国黑色素瘤过度诊断情况进行估计的生态学研究。
BMJ Evid Based Med. 2024 May 22;29(3):156-161. doi: 10.1136/bmjebm-2023-112460.
10
Overdiagnosis in malignant melanoma: a scoping review.恶性黑色素瘤的过度诊断:范围综述。
BMJ Evid Based Med. 2024 Jan 19;29(1):17-28. doi: 10.1136/bmjebm-2023-112341.